SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.